MENY

Gällande vårdprogram skelett- och mjukdelssarkom

Fastställt av Regionala cancercentrum i samverkan 2017-11-22

20. Referenser

1. (VSTB) VfSThB. http://www.blf.net/onko/page1/index.html.

2. Rydholm A. Management of patients with soft-tissue tumors. Strategy developed at a regional oncology center. Acta Orthop Scand Suppl. 1983;203:13-77.

3. "Delays in Referral of Soft Tissue Sarcomas", by G. D. Johnson, G. Smith, A. Dramis, and R. J. Grimer, Sarcoma, V. 2008, Article ID 378574, 7 pages.

4. Gutierrez JC, Perez EA, Moffat FL, Livingstone AS, Franceschi D, Koniaris LG. Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients. Ann Surg. 2007;245(6):952-8.

5. Bhangu AA, Beard JA, Grimer RJ. Should Soft Tissue Sarcomas be Treated at a Specialist Centre? Sarcoma. 2004;8(1):1-6.

6. "Surgical Management of Soft Tissue Tumors: Avoiding the Pitfalls", By Fritz C. Eilber, MD, and Frederick R. Eilber, MD, American Society of Clinical Oncology Educational Book. ASCO 2005.

7. Pretell-Mazzini J, Barton MD, Jr., Conway SA, Temple HT. Unplanned excision of soft-tissue sarcomas: current concepts for management and prognosis. J Bone Joint Surg Am. 2015;97(7):597-603.

8. Gustafson P, Dreinhofer KE, Rydholm A. Soft tissue sarcoma should be treated at a tumor center. A comparison of quality of surgery in 375 patients. Acta Orthop Scand. 1994;65(1):47-50.

9. Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, et al. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 2016;17(9):1261-71.

10. Fletcher CDM, Bridge JA, Hogendoorn PCW, and Mertens F. red. WHO Classification of Tumours of Soft Tissue and Bone. World Health Organization classification of tumours. 4 utg. Lyon: IARC Press; 2013.

11. Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122(23):3673-81.

12. http://www.socialstyrelsen.se/nationellariktlinjerforsjukdomsforebyggandemetoder/.

13. Johnson CJ, Pynsent PB, Grimer RJ. Clinical features of soft tissue sarcomas. Ann R Coll Surg Engl. 2001;83(3):203-5.

14. Grimer R, Judson I, Peake D, Seddon B. Guidelines for the management of soft tissue sarcomas. Sarcoma. 2010;2010:506182.

15. Rydholm A. Improving the management of soft tissue sarcoma. Diagnosis and treatment should be given in specialist centres. BMJ. 1998;317(7151):93-4.

16. Grimer RJ. Size matters for sarcomas! Ann R Coll Surg Engl. 2006;88(6):519-24.

17. Skandinaviska sarkomgruppens hemsida http://www.ssg-org.net/treatment-protocols-and-recommendations/ongoing.

18. Bauer HC, Trovik CS, Alvegard TA, Berlin O, Erlanson M, Gustafson P, et al. Monitoring referral and treatment in soft tissue sarcoma: study based on 1,851 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand. 2001;72(2):150-9.

19. Geijer M, Styring E, Brosjo O, Skorpil M. [Most musculoskeletal soft tissue tumors are benign]. Lakartidningen. 2014;111(38):1578-80.

20. Miller TT. Bone tumors and tumorlike conditions: analysis with conventional radiography. Radiology. 2008;246(3):662-74.

21. Moser RP, Jr., Madewell JE. An approach to primary bone tumors. Radiol Clin North Am. 1987;25(6):1049-93.

22. Grimer R, Athanasou N, Gerrand C, Judson I, Lewis I, Morland B, et al. UK Guidelines for the Management of Bone Sarcomas. Sarcoma. 2010;2010:317462.

23. Group ESESNW. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102-12.

24. Grimer RJ, Carter SR, Tillman RM, Abudu A. Early symptoms and diagnosis of bone tumors. J Bone Joint Surg Am. 2001;83-A(7):1107-8.

25. Grimer RJ, Sneath RS. Diagnosing malignant bone tumours. J Bone Joint Surg Br. 1990;72(5):754-6.

26. Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am. 2000;82(5):667-74.

27. Imaging of Bone Tumors and Tumor-Like Lesions: Techniques and Applications. A. Mark Davies, Murali Sundaram, Steven J. James. Springer Science & Business Media, 21 aug. 2009 - 701 sidor.

28. Coates M. Ultrasound and soft-tissue mass lesions--a note of caution. N Z Med J. 2003;116(1187):U706.

29. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980(153):106-20.

30. AJCC Cancer Staging Manual Editors: Edge, S., Byrd, D.R., Compton, C.C., Fritz, A.G., Greene, F.L., Trotti, A. (Eds.) 7th edition, ISBN 978-0-387-88440-0 Springer-Verlag New York, 2010.

31. European Partnership Action Against Cancer consensus g, Borras JM, Albreht T, Audisio R, Briers E, Casali P, et al. Policy statement on multidisciplinary cancer care. Eur J Cancer. 2014;50(3):475-80.

32. Group EESNW. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii100-9.

33. Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treat Rev. 2016;42:56-72.

34. Thenappan A, Halaweish I, Mody RJ, Smith EA, Geiger JD, Ehrlich PF, et al. Review at a multidisciplinary tumor board impacts critical management decisions of pediatric patients with cancer. Pediatr Blood Cancer. 2017;64(2):254-8.

35. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin. 2004;54(2):94-109.

36. Referral guidelines for suspected cancer. London: National Institute for Health and Clinical Excellence; 2005. Clinical Guideline 27. Tilgjengelig fra: http://www.nice.org.uk/nicemedia/pdf/cg027niceguideline.pdf.

37. Trovik CS, Bauer HC, Alvegard TA, Anderson H, Blomqvist C, Berlin O, et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer. 2000;36(6):710-6.

38. Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17(10):1396-408.

39. Liu XW, Zi Y, Xiang LB, Han TY. Periosteal osteosarcoma: a review of clinical evidence. Int J Clin Exp Med. 2015;8(1):37-44.

40. O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235-41.

41. O'Sullivan B, Gullane P, Irish J, Neligan P, Gentili F, Mahoney J, et al. Preoperative radiotherapy for adult head and neck soft tissue sarcoma: assessment of wound complication rates and cancer outcome in a prospective series. World J Surg. 2003;27(7):875-83.

42. Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14(3):859-68.

43. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16(1):197-203.

44. Alektiar KM, Brennan MF, Healey JH, Singer S. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. J Clin Oncol. 2008;26(20):3440-4.

45. Strander H, Turesson I, Cavallin-Stahl E. A systematic overview of radiation therapy effects in soft tissue sarcomas. Acta Oncol. 2003;42(5-6):516-31.

46. Jebsen NL, Bruland OS, Eriksson M, Engellau J, Turesson I, Folin A, et al. Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall. Int J Radiat Oncol Biol Phys. 2011;81(5):1359-66.

47. DuBois SG, Krailo MD, Gebhardt MC, Donaldson SS, Marcus KJ, Dormans J, et al. Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group. Cancer. 2015;121(3):467-75.

48. La TH, Meyers PA, Wexler LH, Alektiar KM, Healey JH, Laquaglia MP, et al. Radiation therapy for Ewing's sarcoma: results from Memorial Sloan-Kettering in the modern era. Int J Radiat Oncol Biol Phys. 2006;64(2):544-50.

49. DeLaney TF, Park L, Goldberg SI, Hug EB, Liebsch NJ, Munzenrider JE, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys. 2005;61(2):492-8.

50. Schwarz R, Bruland O, Cassoni A, Schomberg P, Bielack S. The role of radiotherapy in oseosarcoma. Cancer Treat Res. 2009;152:147-64.

51. Bloch OG, Jian BJ, Yang I, Han SJ, Aranda D, Ahn BJ, et al. Cranial chondrosarcoma and recurrence. Skull Base. 2010;20(3):149-56.

52. Jian BJ, Bloch OG, Yang I, Han SJ, Aranda D, Tihan T, et al. Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma. J Neurooncol. 2010;98(1):101-8.

53. DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Weyman EA, Yeap BY, et al. Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol. 2014;110(2):115-22.

54. Rastrelli M, Tropea S, Basso U, Roma A, Maruzzo M, Rossi CR. Soft tissue limb and trunk sarcomas: diagnosis, treatment and follow-up. Anticancer Res. 2014;34(10):5251-62.

55. Rothermundt C, Whelan JS, Dileo P, Strauss SJ, Coleman J, Briggs TW, et al. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients. Br J Cancer. 2014;110(10):2420-6.

56. Sena biverkningar http://www.blf.net/onko/page6/page14/page14.html.

57. Moureau-Zabotto L, Thomas L, Bui BN, Chevreau C, Stockle E, Martel P, et al. [Management of soft tissue sarcomas in first isolated local recurrence: a retrospective study of 83 cases]. Cancer Radiother. 2004;8(5):279-87.

58. Tinkle CL, Weinberg V, Braunstein SE, Wustrack R, Horvai A, Jahan T, et al. Intraoperative Radiotherapy in the Management of Locally Recurrent Extremity Soft Tissue Sarcoma. Sarcoma. 2015;2015:913565.

59. Torres MA, Ballo MT, Butler CE, Feig BW, Cormier JN, Lewis VO, et al. Management of locally recurrent soft-tissue sarcoma after prior surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 2007;67(4):1124-9.

60. Daigeler A, Zmarsly I, Hirsch T, Goertz O, Steinau HU, Lehnhardt M, et al. Long-term outcome after local recurrence of soft tissue sarcoma: a retrospective analysis of factors predictive of survival in 135 patients with locally recurrent soft tissue sarcoma. Br J Cancer. 2014;110(6):1456-64.

61. Kim HS, Bindiganavile SS, Han I. Oncologic outcome after local recurrence of chondrosarcoma: Analysis of prognostic factors. J Surg Oncol. 2015;111(8):957-61.

62. Loh AH, Navid F, Wang C, Bahrami A, Wu J, Neel MD, et al. Management of local recurrence of pediatric osteosarcoma following limb-sparing surgery. Ann Surg Oncol. 2014;21(6):1948-55.

63. Blackmon SH, Shah N, Roth JA, Correa AM, Vaporciyan AA, Rice DC, et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg. 2009;88(3):877-84; discussion 84-5.

64. Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388(10043):488-97.

65. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879-86.

66. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010;28(5):835-40.

67. Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol. 2012;23(12):3171-9.

68. Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res. 2009;15(3):1096-104.

69. Seddon B, Scurr M, Jones RL, Wood Z, Propert-Lewis C, Fisher C, et al. A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. Clin Sarcoma Res. 2015;5:13.

70. Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol. 1987;5(6):840-50.

71. Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, Martin J, Martinez-Trufero J, Casado A, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011;29(18):2528-33.

72. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):4188-96.

73. Ixoten/vepesid. Poster: Ahlström M, Eriksson M. Trofosfamide and etoposide as a well tolerated palliative treatment in advanced soft tissue sarcoma. CTOS 2015, abstract 187.

74. Schoffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629-37.

75. Leithner A, Schnack B, Katterschafka T, Wiltschke C, Amann G, Windhager R, et al. Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin. J Surg Oncol. 2000;73(1):21-5.

76. Valentin T, Fournier C, Penel N, Bompas E, Chaigneau L, Isambert N, et al. Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Invest New Drugs. 2013;31(6):1626-7.

77. Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol. 2012;30(9):914-20.

78. Stacchiotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, Morosi C, et al. Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol. 2013;24(7):1931-6.

79. Lipplaa A, Dijkstra S, Gelderblom H. Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series. Clin Sarcoma Res. 2016;6:19.

80. Chugh R, Dunn R, Zalupski MM, Biermann JS, Sondak VK, Mace JR, et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol. 2005;23(15):3597-604.

81. Ray-Coquard IL, Domont J, Tresch-Bruneel E, Bompas E, Cassier PA, Mir O, et al. Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. J Clin Oncol. 2015;33(25):2797-802.

82. Azzarelli A, Gronchi A, Bertulli R, Tesoro JD, Baratti D, Pennacchioli E, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer. 2001;92(5):1259-64.

83. Weiss AJ, Horowitz S, Lackman RD. Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol. 1999;22(2):193-5.

84. Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009;45(17):2930-4.

85. Patel SR, Benjamin RS. Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol. 2006;24(1):11-2.

86. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007;25(21):3144-50.

87. Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol. 2012;23(2):501-8.

88. Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26(32):5269-74.

89. Judson I, Verweij J, Gelderblom H, Hartmann JT, Schoffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415-23.

90. Katz D, Boonsirikamchai P, Choi H, Lazar AJ, Wang WL, Xiao L, et al. Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma. Clin Sarcoma Res. 2012;2(1):2.

91. D'Angelo SP, Munhoz RR, Kuk D, Landa J, Hartley EW, Bonafede M, et al. Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma. Oncology. 2015;89(4):205-14.

92. Sanfilippo R, Dileo P, Blay JY, Constantinidou A, Le Cesne A, Benson C, et al. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. Anticancer Drugs. 2015;26(6):678-81.

93. Winter S, Fasola S, Brisse H, Mosseri V, Orbach D. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy. Pediatr Blood Cancer. 2015;62(11):1935-41.

94. Regnier-Rosencher E, Guillot B, Dupin N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol. 2013;68(2):313-31.

95. Becker G, Bottke D. Radiotherapy in the management of Kaposi's sarcoma. Onkologie. 2006;29(7):329-33.

96. Penel N, Le Cesne A, Bui BN, Perol D, Brain EG, Ray-Coquard I, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2011;22(2):452-7.

97. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011;117(21):4939-47.

98. Park MS, Ravi V, Conley A, Patel SR, Trent JC, Lev DC, et al. The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. Clin Sarcoma Res. 2013;3(1):7.

99. Wells M, Macmillan M, Raab G, MacBride S, Bell N, MacKinnon K, et al. Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol. 2004;73(2):153-62.

100. Iwakawa M, Noda S, Yamada S, Yamamoto N, Miyazawa Y, Yamazaki H, et al. Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 breast cancer patients. Breast Cancer. 2006;13(3):300-7.

101. Prochazka M, Granath F, Ekbom A, Shields PG, Hall P. Lung cancer risks in women with previous breast cancer. Eur J Cancer. 2002;38(11):1520-5.

102. Jagsi R, Griffith KA, Koelling T, Roberts R, Pierce LJ. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer. 2007;109(4):650-7.

103. Kaufman EL, Jacobson JS, Hershman DL, Desai M, Neugut AI. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol. 2008;26(3):392-8.

104. Macdonald G, Kondor N, Yousefi V, Green A, Wong F, Aquino-Parsons C. Reduction of carboxyhaemoglobin levels in the venous blood of cigarette smokers following the administration of carbogen. Radiother Oncol. 2004;73(3):367-71.

105. Tonnesen H, Nielsen PR, Lauritzen JB, Moller AM. Smoking and alcohol intervention before surgery: evidence for best practice. Br J Anaesth. 2009;102(3):297-306.

106. Bradley KA, Rubinsky AD, Sun H, Bryson CL, Bishop MJ, Blough DK, et al. Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med. 2011;26(2):162-9.

107. Nath B, Li Y, Carroll JE, Szabo G, Tseng JF, Shah SA. Alcohol exposure as a risk factor for adverse outcomes in elective surgery. J Gastrointest Surg. 2010;14(11):1732-41.

108. Styring E, Billing V, Hartman L, Nilbert M, Seinen JM, Veurink N, et al. Simple guidelines for efficient referral of soft-tissue sarcomas: a population-based evaluation of adherence to guidelines and referral patterns. J Bone Joint Surg Am. 2012;94(14):1291-6.

109. Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl. 1994;259:1-31.

110. Zaikova O, Sundby Hall K, Styring E, Eriksson M, Trovik CS, Bergh P, et al. Referral patterns, treatment and outcome of high-grade malignant bone sarcoma in Scandinavia-SSG Central Register 25 years' experience. J Surg Oncol. 2015;112(8):853-60.

111. Mertens F, Tayebwa J. Evolving techniques for gene fusion detection in soft tissue tumours. Histopathology. 2014;64(1):151-62.

112. Coindre JM, Terrier P, Bui NB, Bonichon F, Collin F, Le Doussal V, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol. 1996;14(3):869-77.

113. Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(1):350-62.

114. Miettinen M. Soft tissue tumors - from grading to specific mutations. Arch Pathol Lab Med 2006;130(Special section - pathology of soft tissue tumors):1446-.

115. Brian P. Rubin, Cristina R. Antonescu, Francis H. Gannon, Jennifer Leigh Hunt, Carrie Y. Inwards, Michael Jeffrey Klein, Jeffrey S. Kneisl, Anthony G. Montag, Terrance D. Peabody, John D. Reith, Andrew E. Rosenberg, Thomas Krausz, and for the Members of the Cancer Committee, College of American Pathologists (2010) Protocol for the Examination of Specimens From Patients With Tumors of Bone. Archives of Pathology & Laboratory Medicine: April 2010, Vol. 134, No. 4, pp. e1-e7.

116. Gustafson P, Akerman M, Alvegard TA, Coindre JM, Fletcher CD, Rydholm A, et al. Prognostic information in soft tissue sarcoma using tumour size, vascular invasion and microscopic tumour necrosis-the SIN-system. Eur J Cancer. 2003;39(11):1568-76.

117. Carneiro A, Bendahl PO, Engellau J, Domanski HA, Fletcher CD, Rissler P, et al. A prognostic model for soft tissue sarcoma of the extremities and trunk wall based on size, vascular invasion, necrosis, and growth pattern. Cancer. 2011;117(6):1279-87.

118. Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80. J Cancer Res Clin Oncol. 1983;106 Suppl:21-4.

119. Picci P, Rougraff BT, Bacci G, Neff JR, Sangiorgi L, Cazzola A, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol. 1993;11(9):1763-9.

120. Broders AC, Hargrave R, Meyerding HW. Pathological features of soft tissue fibrosarcoma with special reference to the grading of its malignancy. Surg Gynecol Obstet 1939;69:267-80.

121. Angervall L, Kindblom LG. Principles for pathologic-anatomic diagnosis and classification of soft-tissue sarcomas. Clin Orthop Relat Res. 1993(289):9-18.

122. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977;40(2):818-31.